HOME >> BIOLOGY >> NEWS
Virus found to carry antibiotic against E. coli

COLLEGE STATION -- Part of a small virus that attacks only bacteria acts like an antibiotic to destroy E. coli, researchers with the Texas Agricultural Experiment Station have found.

A report on the antibiotic action of the small virus, "Q Beta," is reported in this week's Science magazine. The research was funded by the National Institute of Health's general medicine institute.

The finding provides a new approach for designing drugs to combat many serious bacterial diseases, including E. coli, pneumonia, staph infection, ear infections, Lyme's disease and cholera in humans, as well as bacterial diseases in pets, livestock and crops, according to Tom Bernhardt, biochemistry doctoral student, and Dr. Ing-Nang Wang, a lead investigator on the project.

New types of antibiotics are increasingly important because many disease- causing bacteria have become resistant to antibiotics, reducing the number of medicines available for treatment. Researchers fear that continued resistance could result in epidemics of diseases once thought controlled by antibiotics.

The research at the Experiment Station found that a protein within the small virus, known as a "phage" in scientific circles, does the same thing to bacterial cell walls as antibiotics. It blocks the ability of the cell to make its tough outer wall so bacteria blow up or destroy themselves rather than divide into more cells. Dead bacterial cells means an end to the illness.

"This 'protein antibiotic' is the answer to an old mystery: how Q-beta and other small phage kill bacteria," said Dr. Ry Young, a biochemist in whose lab at Texas A&M University the work was done, in collaboration with Dr. Douglas K. Struck, a medical biochemistry and genetics professor. "Basically they let the cell commit suicide by dividing without making a new cell wall."

The research team expects pharmaceutical companies to further explore phages for new types of antibiotics. "Ideally, the small bit
'"/>

Contact: Kathleen Phillips
ka-phillips@tamu.edu
979-845-2872
Texas A&M University
21-Jun-2001


Page: 1 2

Related biology news :

1. Virus known for its photo ops makes its movie screen debut
2. Viruses clear bacterial contamination in chickens
3. Viruses may be environmentally friendly decontaminants
4. The Virus-Cancer Link: Examining the Role of Viruses in the Development of Cancer
5. Virus researchers close in on the secret life of DNA
6. Virus beats food bug
7. West Nile Virus cases analyzed for prevalence and symptoms
8. West Nile Virus can cause polio-like symptoms
9. Antibodies critical for fighting West Nile Virus infection
10. CDC Telebriefing: Smallpox educational activities and West Nile Virus update
11. West Nile Virus capsid protein causes encephalitic inflammation by triggering cell suicide

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Virus found carry antibiotic against coli

(Date:10/22/2014)... Medicine® scientists helps explain how bipolar disorder affects the ... therapies to treat the mental illness. , Scientists ... method recognized with the 2014 Nobel Prize in ... from mice with bipolar-like behaviors. In the synapses (where ... structures with concentrated levels of ANK3 -- the gene ...
(Date:10/22/2014)... , Oct. 20, 2014  Leading identity analyst firm ... half of the world,s population will have a chip-based ... Europe . Asia , ... market accounting for more than 60% of all National ... Acuity,s report  -- "The Global National eID ...
(Date:10/19/2014)... in India over the last 30 years contributed ... growth during that time, according to a new ... Change ., "Energy access is fundamental to development: ... including education, communication, and health," says IIASA researcher ... increased energy access is widely agreed to be ...
Breaking Biology News(10 mins):Bipolar disorder discovery at the nano level 2Half the World's Population Will Have Chip-Based National Electronic Identity (eID) Cards by 2018 2Improved electricity access has little impact on climate change 2
(Date:10/25/2014)... , October 24, 2014 ... Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals Inc. ... ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... research on these five companies can be accessed at: ... Thursday, October 23, 2014, ended on a positive note ...
(Date:10/22/2014)... BOSTON , Oct. 22, 2014  Actavis ... specialty pharmaceutical company, and Rhythm, a biopharmaceutical company, today ... to acquire Rhythm,s wholly owned subsidiary, Rhythm Health, Inc., ... for the treatment of diabetic gastroparesis and other GI ... successful Phase 2 trial of relamorelin for the treatment ...
(Date:10/22/2014)... WriteResult, LLC – a premier provider of ... a team of researchers from Yale University’s School of ... to provide electronic questionnaire data collection through use of ... in May, aims to evaluate the impact of a ... and participation in urban agriculture to impact their consumption ...
(Date:10/22/2014)... ROCKVILLE, Md. , Oct. 22, 2014   ... company developing novel pathogen-specific therapies for serious infections and ... Office has issued a Notice of Allowance for a ... product in its C. difficile program, SYN-004. This ... to SYN-004 in the U.S. and adds to the ...
Breaking Biology Technology:Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 2Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 3Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 4Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin 5myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 2myPROpad™ Topic of Panel Discussion at the Yale Food Systems Symposium 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 2Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 3Synthetic Biologics Announces Allowance of Key U.S. Composition of Matter Patent for C. difficile Program 4
Cached News: